Three of the world's biggest beauty houses just told us exactly where the next 12 months of skincare are headed — AI-modeled formulas, biotech actives, and technology you can actually patent. The brands that move on this intelligence first will own the shelf space. Here's what happened this month, and what it really means for whoever launches next.
Leading Brand Moves
L'Oréal — AI Enters the R&D Core
L'Oréal used its tenth anniversary at VivaTech 2026 (17–20 June) to unveil a wide-ranging "Beauty Odyssey" of AI and science-driven innovations, reinforcing its position as the industry's technology bellwether.
- Expanded its AI partnership with NVIDIA, integrating the ALCHEMI machine-learning framework into its Research & Innovation ecosystem to predict how molecules perform and interact at an atomic scale — effectively building an AI engine for new formulation discovery.
- Completed its acquisition of Kering Beauté in March, adding the House of Creed and 50-year exclusive fragrance and beauty licences for Bottega Veneta and Balenciaga.
- At CES 2026, debuted two light-based devices — an infrared hair styler and a prototype LED face mask — both named CES Innovation Award honorees, extending its "augmented beauty" device strategy.
The NVIDIA tie-up matters more than the headline suggests. Once atomic-scale molecule prediction becomes routine at a company L'Oréal's size, the competitive edge for everyone downstream stops being "who can invent a novel active" and starts being "who can turn an AI-modeled formula into a stable, manufacturable product fastest." That's a race measured in days and weeks, not fiscal quarters — the brands that win it will be the ones whose production partner can sample and iterate at the same speed the trend is moving. The Kering Beauté deal is a separate signal worth watching: luxury fragrance keeps consolidating into fewer hands, which will make licensed-brand fragrance briefs scarcer and more competitive for independent labels.
Estée Lauder — Turnaround Gains Traction, Science-Led Investment
Estée Lauder Companies posted its strongest quarter in several years, with fiscal Q1 2026 net sales up 4% to US$3.48bn, beating analyst estimates and lifting its full-year outlook.
- Fragrance led growth at +13%, driven by Tom Ford's Oud Voyager and Jo Malone London; skincare rose 3% on strength in La Mer and the core Estée Lauder line.
- Took a minority stake in clinical skincare brand 111SKIN, anchored on its proprietary NAC Y2 antioxidant technology — signalling continued appetite for science-backed, dermatologist-positioned brands.
- Continues to expand distribution via TikTok Shop and Amazon Premium Beauty across the US, Canada, Malaysia and Singapore, underscoring the channel shift toward social commerce.
It's telling that fragrance, not skincare, is carrying Estée Lauder's turnaround. Consumers are currently more willing to pay up for sensorial, gift-worthy categories than for another "innovative" moisturizer — a positioning cue worth testing before the next development budget gets locked in. The 111SKIN investment tells its own story too: "clinical-adjacent" credibility, anchored to a named, patentable technology, is still the safest asset a beauty brand can hold. The interesting question for the rest of the market is whether that credibility has to be bought at Estée Lauder's price tag, or whether it can be built into a formula from day one.
Shiseido — Betting on Proprietary Technology and AI Formulation
Shiseido's new 2030 Medium-Term Strategy sharpens its focus on four categories — skincare, suncare, fragrance and derma — with a commitment to integrate more than ten new proprietary technologies by 2028.
- Its AI-powered formulation platform VOYAGER, built with over 500,000 historical formulation data points, produced its first commercial output: a mist-type suncare product launching in summer 2026.
- Introduced WASHABLE LOCK TECHNOLOGY, an oil-based mascara film that holds curl yet rinses off with warm water, resolving a long-standing formulation trade-off.
- Continues active publication of skin-biology research (e.g. sugar exposure and cellular aging, arterial blood flow and facial sagging), reinforcing its dermatology-grade brand positioning.
Shiseido leaning this hard into proprietary, patentable technology — rather than chasing trend ingredients — reads as a defensive move as much as an offensive one. Indie and K-beauty brands can copy a hero ingredient in a season; they can't easily copy a named delivery technology built on hundreds of thousands of data points. It's a reminder that a good ingredient story is table stakes now, and a defensible, ownable technology is what actually protects margin once that ingredient goes mainstream — something worth building into a formula brief from the start, not bolting on after launch.
Ingredient & Formulation Trends to Watch
Across markets, 2026 R&D conversation is converging around what analysts are calling "Longevity Beauty" and "Metabolic Skincare" — a move away from aggressive, corrective actives toward formulas that repair, protect and strengthen skin over time.
- Next-generation peptides: multifunctional and signalling peptides designed for specific tasks — collagen stimulation, redness reduction, barrier repair — rather than single-action actives.
- Exosomes & bioengineered extracellular vesicles: increasingly non-human, biotech-derived sources are favoured for consistency and regulatory clarity; positioning is shifting from novelty to core "messenger" technology in regenerative formulas.
- Postbiotics & microbiome care: fermented actives and barrier-adaptive molecules continue to move from niche to mainstream, especially for sensitised and reactive skin.
- PDRN, NAD+ and ectoin: supporting the same longevity narrative, with ectoin in particular gaining traction as a hydration shield against urban stressors and UV.
- AI-assisted formulation: with L'Oréal's NVIDIA ALCHEMI collaboration and Shiseido's VOYAGER platform both reaching commercial output this year, AI-predicted formulation is moving from R&D pilot to standard practice among top-tier brands.
A word of caution alongside the enthusiasm: exosomes and "next-gen" peptides are currently outrunning their own supply chains. The marketing language is ready long before sourcing, stability data and regulatory positioning are. The brands that win with these actives will be the ones who treat the ingredient story as a starting point for a real formulation conversation — sourcing, stability, compliance — rather than a finished pitch deck. That distinction is exactly where this quarter's winners and also-rans will separate.
The Window Worth Acting On
Put the three stories together and a pattern emerges: the gap between global leaders and the mid-market is no longer about who has access to a trendy ingredient — everyone does. It's about who can validate that ingredient's performance and stability, build a credible technology story around it, and move from concept to pilot batch before the trend peaks. That window is open right now, and it tends to close fast once an active goes mainstream.
If any of the moves above sparked an idea for your next launch — a peptide formula worth prototyping, a technology story worth naming, a market worth testing — this is the week to start that conversation. Reply to this report or reach out to your account manager, and let's see what's possible.
